Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2000

View Archived Issues

Gene therapy results in neuroprotection, functional regeneration in primate PD model

Eukarion receives grant funds for SCS drug development

Recombinant human NGF safe but ineffective in diabetic polyneuropathy

HIV disease progression unaffected by the addition of HIV-1 immunogen to therapy

SynGenix and Glaxo Wellcome collaborate on novel pain therapies

Medicure licenses cardiovascular therapeutics from George Washington University

KS Biomedix and York Medical sign high-affinity antibody deal

Company Profile: Calyx

Seattle Genetics evaluates SGN-15/Taxotere combination in phase II

DIRECT trial begins for prevention and progression of retinopathy in diabetic patients

Hemosol receives go-ahead to begin phase I study of HML-115

Merger talks begin between two major Japanese pharmaceutical companies

U. of Michigan and Parke-Davis identify slow tight-binding inhibitor of KDO-8-P

SAR leading to APC-2059, a potent and selective human mast cell tryptase inhibitor

Pharmacokinetics, distribution and elimination of human CXC chemokine in mice

Novel, orally active iron chelator APO-363: preclinical pharmacokinetics reported at AAPS

RWJ-67657 advances to human studies: PK and cytokine inhibition determined in healthy subjects

Actinomycin D presented in Singapore as potential stroke-related incontinence therapy

153Sm-EDTMP: further beneficial effects in prostate cancer patients with bone lesions

AASLD news: optimal phase III anti-HBV dose of Coviracil selected from phase I/II data

CPMP recommends approval of Neurobloc for treatment of cervical dystonia

New 5-HT7 receptor antagonists designed at SB

SmithKline Beecham reveals new chemokine receptor antagonists and their potential use

Novel series from AHP with FSH-antagonist activity and utility as contraceptives

Synthesis and biological activity of 5-ht6 receptor antagonists reported by Canadian company

Heptazyme, an exciting new approach to chronic hepatitis C, covered at AASLD

New Gruenenthal compounds bind with high affinity to sodium and calcium channels

Temple researchers identify biologically active anticancer (Z)-styryl benzylsulfones

Recent AHP patent describes calcitonin inducers particularly useful for osteoporosis

Recent patent covers Bayer's newest agents for HBV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...